We are bringing AI to the fight against breast cancer with leading clinical evidence and the latest deep learning technology.
We are working with breast clinicians to continually improve the clinically proven deep learning algorithms in Transpara®. We are committed to further improve accuracy, consistency and reduce unnecessary recalls, a common cause of anxiety for women undergoing mammography.
ScreenPoint Medical was founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady, world leading experts in quantitative breast image analysis and computer aided detection.
ScreenPoint Medical was founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady, world leading experts in quantitative breast image analysis and computer aided detection.
They have led research projects in the field for over twenty years and have made important contributions to leading breast imaging products.
Prof Karssemeijer says, “I started ScreenPoint Medical because I wanted my academic work to have a greater impact beyond the publication of scientific papers. I knew our work held out the promise to ultimately improve breast cancer survival rates and recognised the huge potential of my university team to develop a really outstanding product. By using the technological advances of Deep Learning Artificial Intelligence, we have overtaken current CAD systems to produce faster and more accurate results.”
The resulting product, Transpara, has featured in multiple peer-reviewed publications that show it enables significant clinical improvements to the timely diagnosis of breast cancer.
The resulting product, Transpara, has featured in multiple peer-reviewed publications that show it enables significant clinical improvements to the timely diagnosis of breast cancer.
“Transpara is now being used by radiologists in clinical practice, but this is only the beginning! We are constantly innovating and we will continue to help doctors to achieve higher breast cancer survival rates and at the same time, minimise patient distress and the cost of unnecessary treatments.”
“But we always remember that our excellence in innovation must be matched by the way we run our business. We are lean, focused on producing optimum results with cost savings passed on to our customers.”
Co-Founder of ScreenPoint Medical, Sir Michael Brady, was known internationally for his ground-breaking work in robotic image analysis at the University of Oxford but the death of his mother in law from breast cancer, caused him to change direction:
“I wanted to understand why the medical profession wasn’t able to do a better job of detecting breast cancers at an earlier stage when they were more treatable. So I decided to move away from robotics and concentrate on the analysis of breast scans.’
My colleagues and I developed a mathematical model of the passage of X-rays through female breast tissue, a fundamental step towards developing a system able to recognise potential tumours.
I met Nico Karssemeijer from Nijmegen University in 2000 when he was giving a keynote lecture on parallel research.
Both of us wanted to help radiologists identify potential cancers faster and at an earlier stage and to increase the chances of more women surviving breast cancer.
In 2014 we started ScreenPoint Medical. We built a superb team of scientists to develop a unique system, Transpara, a blend of classic physics and deep learning artificial intelligence, presented as a decision support tool to increase efficiency.
There are fewer and fewer radiologists specialising in reading mammograms at a time when breast cancer incidence is increasing worldwide.
ScreenPoint are the only people that combine deep understanding of the physics, knowledge of clinical workflow and deep learning AI techniques to improve accuracy and speed of detection. Transpara is the world leader!”
Professor Sir Michael Brady FRS FMedSci FREng is a world leading scientist in computer vision, robotics, and medical image analysis. He co-authored Mammographic Image Analysis (Kluwer 1999) with Ralph Highnam; the ideas introduced in this monograph – together with some later innovative developments by Nico Karssemeijer and colleagues – provided the basis for Volpara density. As well, Brady has co-founded and steered several small high-growth technology companies to success. In addition to Matakina, he is a Founder Director of: Perspectum Diagnostics, Mirada Medical, and Guidance Navigation; as well as being Chairman of: Acuitas Medical, IRISS Medical, Colwiz, and was until recently Deputy Chairman of Oxford Instruments plc.
Anirudha has strong cross-functional expertise across general management, strategy, product & innovation management, and sales operations addressing customers across the world. In his function as vice president of New X-ray Markets at Siemens Healthineers, he is responsible for identifying and bringing new business opportunities in the X-ray products business line to the market. In his previous role, he was the head of the global value segment X-ray products where he drove the definition and development of a new mobile C-arm platform. He has also served as the head of CRM and sales analytics and as business manager for South Asia in prior positions. As a non-executive director at ScreenPoint Medical, he is jointly working towards improved breast cancer diagnosis using artificial intelligence.
PRINCIPAL, ONSITE
Allyson joined Insight in 2012. Previously, she was a strategy consultant in the markets and customers practice at Monitor Group, where she advised multi-national companies on growth strategy, product innovation, acquisitions, scenario planning and pricing strategy. She worked in a variety of industries including Pharmaceutical, Insurance, and Chemicals.
Allyson graduated with high honors from the Huntsman Program in International Studies and Business at the University of Pennsylvania. She is fluent in Spanish.
Dr. Rachel Brem is the Director of Breast Imaging and Intervention at The George Washington University Medical Center, Professor of Radiology and the Vice Chairman of the Department of Radiology. In 2015 Dr. Brem was named the Program Leader for Breast Cancer at the GW Cancer Center. Dr. Brem completed her undergraduate studies at Brandeis University followed by medical school at Columbia University where she graduated with honors. Dr. Brem completed both her Diagnostic Radiology Residency and Breast Imaging Fellowship at the John Hopkins Medical Institutions. Since completion of her training Dr. Brem was on the faulty at John Hopkins as the Director of Breast Imaging. Currently she is the Director of Breast Imaging and Interventional Center at the George Washington Medical Institution and Professor of Radiology. Dr. Brem’s research and clinical interest includes Minimally Invasive Breast Biopsy as well as New Technologies for the Earlier Diagnosis of breast cancer focusing Whole Breast Ultrasound for women with dense breast tissue for improved breast cancer detection and risk assessment, Artificial Intelligence for breast cancer detection and Molecular Imaging of the Breast. She currently directs multi-institutional clinical trials evaluating novel approaches to improved diagnosis of breast cancer and is the recipient of numerous honors and awards including Best Cancer Doctors (Newsweek), Castle Connolly Best Doctors for Cancer and Top Doctor, Jewish Woman International’s Ten Women to Watch, the prestigious fellowship in the American College of Radiology and the Society of Breast Imaging. She is an internationally recognized expert on Breast Cancer who is sought to speak on the subject nationally and internationally. Dr. Brem has extensively published, and is also committed to mentoring of students and residents. She is on the scientific advisory board of The Prevent Cancer Foundation as well as FORCE (Facing our risk of cancer, for women who are BR CA positive) and is a member of the Board of the Katzen Cancer Research Center. She currently serves on the Board of Directors of Delphinus Medical Technologies, Dilon Technologies and Screenpoint Medical. Previously she served on the Board of Directors of iCAD, inc from 2002-2019.
Prior to the Covid pandemic, Dr. Brem was the Director of the George Washington University Mobile Mammography program (Mammovan), a mobile van that brings mammography to underserved communities to optimize the care of all women.
Dr. Brem was part of the formation of the Brem Foundation to Defeat Breast Cancer in 2004 with a group of committed patients and friends who have worked diligently to support risk based breast cancer screening as well as education and clinical care in the underserved community. The Brem Foundation was instrumental in passing dense breast legislation in the District of Columbia which has the highest death rate from cancer nationally.
Mark Koeniguer has over 25 years of healthcare industry experience launching innovative products and leading high-performance teams in domestic and international markets. He has been instrumental in launching and scaling many industry-first technologies including the first Computer Aided Detection algorithm for the early detection of breast cancer, the first mammography analytics platform and a multi-point risk stratified breast screening scorecard.
Prior to his serial entrepreneurial ventures, Mark held various executive leadership positions in Finance, Operations, Sales and Marketing for GE Healthcare. He holds a finance degree from the University of Iowa, and an MBA from the University of Wisconsin, Madison.
Professor Nico Karssemeijer is a leading scientist in breast cancer imaging and has been one of the pioneers of computer-aided detection, playing a key role in its development and adoptation in breast cancer screening. He was closely involved in the development of the R2 ImageChecker, the first mammography CAD product. He also played an important role in implementing digital mammography in the European screening programs, by initiating and leading EU funded projects in which breast screening workstations were developed that are marketed today by major vendors. He is a Professor in the Department of Radiology, Radboud University, Nijmegen, The Netherlands, and he is co-founder of Matakina Ltd and of QView Medical Inc.
Pieter Kroese has extensive international experience in general, commercial and financial management, and has always been intensively involved in strategy development. He has a background in various industries, leading organisations of up to 400 people. He also developed hands-on entrepreneurial experience as co-founder of a technical startup company. During the last 7 years, Pieter has primarily been working with software development companies. He joined ScreenPoint in 2018 and is responsible for all business activities, driving the commercial focus and growth of the company, as well as assuming responsibility for operations and finance.
Jennifer Harvey is Professor and Chair at the University of Rochester Department of Imaging Sciences. Harvey is an international expert in breast imaging and the early detection of breast cancer. Previously, she was on faculty at the University of Virginia for 26 years, leading its Division of Breast Imaging, Breast Cancer Program, and serving as vice-chair for Education and Faculty Development. Dr. Harvey’s primary research interest is mammographic breast density and the association with breast cancer risk.
Laurie Margolies, MD, Director of Breast Imaging at Mount Sinai Health System, an American College of Radiology fellow and past-President of the New York Breast Imaging Society. Margolies received her medical degree from Yale School of Medicine and has been in practice for more than 20 years. Her research interests include health care disparities, breast MRI, breast density and digital breast tomosynthesis. Dr. Margolies is an uncompensated consultant for ScreenPoint Medical.
Dr. Ritse Mann is a breast and interventional radiologist at the Radboud University Medical Center in Nijmegen and the Netherlands Cancer Institute in Amsterdam and is leading clinical breast imaging research at both institutions. His areas of interest include breast cancer screening, breast MRI, minimal invasive therapy and the use of artificial intelligence for screening, diagnosis and therapy selection of breast cancer. Dr. Mann is a member of the executive board of the European society of breast imaging (EUSOBI) since 2015 and chairing its scientific committee and the program planning committee of the annual meeting.
ScreenPoint Medical is a fast growing scale up breast AI company which is continually looking for the best talent to strengthen all our teams to help us bring AI to the fight against breast cancer.
We are proud to work with some of the world’s leading organizations.
Transpara is a multi vendor solution and is compatible with most 2D and 3D mammography and PACS vendors.
The Most Clinically Validated Breast AI Featured in 4 Significant Peer-Reviewed Studies in Past 6 Months, Better Workflow to Increase
Read moreOur Nijmegen office was visited by a Netherlands-based news crew the week of August 1. What was the big news?
Read moreRandomized Controlled Trial for Breast AI as Second Reader: Preliminary Results Published in The Lancet Oncology Transpara®-assisted workflow helps
Read morePress Release From Lancet Oncology: The AI in use is Transpara First randomised trial finds AI-supported mammography screening is safe
Read moreResearch from Mayo Clinic and UCSF find that the combination of Transpara ® Exam Score with Volpara TruDensity® can predict
Read more
Largest Radiology Practice in the Washington, DC Area, Fairfax Radiology Performs Over 100,000 Mammograms a Year NATIONAL HARBOR, Md., May
Read more